BioSpecifics Technologies Corp (NASDAQ:BSTC) issued its earnings results on Friday. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.01, Bloomberg Earnings reports. BioSpecifics Technologies Corp had a net margin of 43.06% and a return on equity of 20.65%. The firm had revenue of $6.52 million during the quarter, compared to analysts’ expectations of $6.59 million.
Shares of BioSpecifics Technologies Corp (BSTC) opened at $43.63 on Friday. The company has a market cap of $313.66, a price-to-earnings ratio of 27.44 and a beta of 1.64. BioSpecifics Technologies Corp has a 52-week low of $41.95 and a 52-week high of $58.79.
Several research analysts recently issued reports on the stock. BidaskClub cut shares of BioSpecifics Technologies Corp from a “sell” rating to a “strong sell” rating in a report on Friday, August 18th. HC Wainwright set a $72.00 target price on shares of BioSpecifics Technologies Corp and gave the stock a “buy” rating in a report on Thursday, August 10th. Finally, Zacks Investment Research raised shares of BioSpecifics Technologies Corp from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th.
BioSpecifics Technologies Corp Company Profile
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with MarketBeat.com's FREE daily email newsletter.